16 December 2016 - PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated products supplied by Zimmer Biomet New Zealand (“Zimmer Biomet”) in Part III of Section H of the Pharmaceutical Schedule from 1 March 2017.

In summary, this proposal would result in:

• Approximately 12,500 products, which are already supplied to DHB Hospitals, being supplied by Zimmer Biomet under a proposed national agreement. This agreement would not be a sole supply agreement, and DHBs would continue to be able to purchase other brands of orthopaedic implants and associated products.
  
• Zimmer Biomet providing educational services that will be tailored to suit the needs of individual DHB Hospitals in format and time as required by DHB Hospitals.
  
• Estimated total savings to DHBs of approximately $970,000 per annum, based on current usage. Pricing for orthopaedic implants and associated products would not be increased before 1 March 2020 subject to any prior termination of the agreement.
  

Read PHARMAC Consultation